Skip to contentH
HCW Biologics Inc.
H
HCWBHCW Biologics Inc. Q1 2023 · 10-Q
Revenue$41.88K$41.88K−98.7% vs Q1 2022 Net Income-$5.07M-$5.07MN/M vs Q1 2022 EPS Diluted-$0.14-$0.14N/M vs Q1 2022 Gross Profit$12,533−99.3% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
HCW Biologics Inc. · CIK 1828673 · Engraved from SEC EDGAR
Operating Cash Flow-$3,638,213N/M Free Cash Flowderived-$3,938,598N/M Margins · derivedGross margin29.9%−27.5 pt vs Q1 2022
Operating margin-12798.9%−12738.6 pt vs Q1 2022
Net margin-12106.8%−12040.8 pt vs Q1 2022
ended Mar 31, 2023 · filed May 9, 2023 · 39 d after period end